<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01812174</url>
  </required_header>
  <id_info>
    <org_study_id>2010-01</org_study_id>
    <secondary_id>G120115</secondary_id>
    <nct_id>NCT01812174</nct_id>
  </id_info>
  <brief_title>On-X Heart Valve - 17mm Aortic and 23mm Mitral</brief_title>
  <official_title>On-X Heart Valve - 17mm Aortic and 23mm Mitral</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>On-X Life Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>On-X Life Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the hemodynamic and hemolytic properties of two additional smaller size&#xD;
      valves to the On-X line of valves already approved by FDA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to assess the safety and efficacy of the 17mm On-X Aortic&#xD;
      Prosthetic Heart Valve and the 23mm On-X Mitral Prosthetic Heart Valve when used to replace&#xD;
      diseased aortic or mitral valves in human subjects.&#xD;
&#xD;
      The On-X 17mm aortic valve will be implanted in approximately 20 and at least 15 patients who&#xD;
      will be followed for at least 1 year. Patients will be any age and will require this size&#xD;
      valve as determined in surgery but will be recruited prior to surgery based on results of&#xD;
      preoperative screening tests.&#xD;
&#xD;
      Enrollment into the 23mm mitral arm of the study has been terminated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2011</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients in one arm are recipients of the 17mm On-X Aortic Valve. Patients in the second arm are recipients of the 23mm On-X Mitral Valve. Since double valve cases are exclusionary, these two arms are mutually exclusive and non-randomized.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamics as a measure of performance</measure>
    <time_frame>1-year</time_frame>
    <description>Pressure gradient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Valve-related adverse events as a measure of safety</measure>
    <time_frame>1-year</time_frame>
    <description>Composite rate of thromboembolism, bleeding, structural dysfunction, endocarditis, non-structural dysfunction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Valve Disease</condition>
  <arm_group>
    <arm_group_label>17mm On-X Aortic Heart Valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the 17mm On-X aortic heart valve as a replacement for diseased native or prosthetic aortic heart valve.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>23mm On-X Mitral Heart Valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the 23mm On-X mitral heart valve as a replacement for diseased native or prosthetic mitral heart valve.&#xD;
Enrollment into the 23mm On-X mitral arm has been terminated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>17mm aortic valve (On-X )</intervention_name>
    <description>Heart aortic valve replacement surgery: 17mm Aortic</description>
    <arm_group_label>17mm On-X Aortic Heart Valve</arm_group_label>
    <other_name>On-X prosthetic heart valve</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>23mm mitral valve (On-X)</intervention_name>
    <description>Heart mitral valve replacement surgery: 23mm Mitral</description>
    <arm_group_label>23mm On-X Mitral Heart Valve</arm_group_label>
    <other_name>On-X prosthetic heart valve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of any age; unless waived by local IRB assent of the patient and in all cases&#xD;
             consent of parent or legally authorized representative is required if a patient is&#xD;
             under the age of majority and not legally emancipated.&#xD;
&#xD;
          2. Patients who are sufficiently ill to warrant replacement of their diseased natural or&#xD;
             prosthetic valve, based on standard cardiovascular diagnostic workups.&#xD;
&#xD;
          3. Patients who are in sufficient satisfactory condition, based on the physical exam and&#xD;
             investigator's experience, to be an average or better operative risk, (i.e., likely to&#xD;
             survive one year postoperatively).&#xD;
&#xD;
          4. Patients who require an isolated aortic valve replacement size 17 mm or isolated&#xD;
             mitral valve replacement size 23mm.&#xD;
&#xD;
          5. Patients who are geographically stable and willing to return to the implanting center&#xD;
             for follow-up visits.&#xD;
&#xD;
          6. Patients or legally authorized representatives who are adequately informed of their&#xD;
             participation in the clinical study and what will be required of them in order to&#xD;
             comply with the protocol.&#xD;
&#xD;
          7. Patients requiring concomitant cardiovascular surgery, such as coronary bypass may be&#xD;
             included in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients who are pregnant, planning to become pregnant or are lactating. 2 Patients who&#xD;
        have a noncardiac progressive disease, which in the investigator's experience produces an&#xD;
        unacceptable increased risk to the patient.&#xD;
&#xD;
        3 Patients who have a documented history of substance (drug or alcohol) abuse or are prison&#xD;
        inmates.&#xD;
&#xD;
        4. Patients with a previous prosthetic valve, where it is not being replaced by a study&#xD;
        valve, or patients requiring multiple valve replacement.&#xD;
&#xD;
        5. Patients with active endocarditis or active myocarditis. 6 Patients who require&#xD;
        tricuspid or pulmonic valve replacement. 7. Patients who have not agreed to return for the&#xD;
        required number of follow-up visits or who are geographically unavailable for follow-up.&#xD;
&#xD;
        8. Patients who cannot be maintained on long-term anticoagulant therapy. 9. Patients with&#xD;
        non-cardiac illness resulting in a life expectancy of less than 1-year.&#xD;
&#xD;
        10. Patients previously enrolled and implanted in this trial may not re-enter after&#xD;
        withdrawal.&#xD;
&#xD;
        11. Patients already enrolled in another investigational device or drug study (nor can&#xD;
        enrolled patients be enrolled in other studies).&#xD;
&#xD;
        12. Patients with acute preoperative neurological deficit, myocardial infarction, or&#xD;
        cardiac event who have not returned to baseline for at least 30-days prior to enrollment.&#xD;
&#xD;
        13. Patients with aortic aneurysm or other medical condition that creates a higher than&#xD;
        usual risk of surgical complication.&#xD;
&#xD;
        14. Patients who are prisoners or mentally ill, and pediatric patients who are incapable of&#xD;
        understanding their assent as judged by the principal investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidney Levitsky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Sylvester, BS</last_name>
    <phone>678-290-4304</phone>
    <email>Sylvester.Karen@cryolife.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gretchen Wilderspin, MS</last_name>
    <phone>678-290-4309</phone>
    <email>Wilderspin.Gretchen@cryolife.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Reemtsen, MD</last_name>
      <phone>501-364-5858</phone>
      <email>BReemtsen@uams.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gina Calhoun</last_name>
      <phone>501-364-5827</phone>
      <email>CalhounGR@archildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Lawrence Greiten, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josh Daily, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsey Gallant, BN</last_name>
      <phone>207-662-1489</phone>
      <email>BGallant@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Reed Quinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan, C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Heart Center Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Morales, MD</last_name>
      <phone>513-803-9150</phone>
      <email>David.Morales@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Tricia Heile</last_name>
      <phone>513-803-5267</phone>
      <email>Tricia.Heile@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Morales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roosevelt Bryant, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Byrnes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Taylor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel Kwiatkowski, MD</last_name>
      <phone>614-355-6788</phone>
      <email>Pawel.Kwiatkowski@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Patrick McConnell, MD</last_name>
      <phone>614-722-3102</phone>
      <email>Patrick.McConnell@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick McConnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma/Children's Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center - Dallas Children's</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Gangemi, MD</last_name>
      <phone>434-924-9061</phone>
      <email>JJG5D@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachael Simon, BSN</last_name>
      <phone>434-2437653</phone>
      <email>RMG5R@hscmail.mcc.virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Gangemi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Bridge Children's - Tacoma General Hospital</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meridith Barnhart</last_name>
      <phone>253-403-7252</phone>
      <email>Meredith.Barnhart@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Allen Graeve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayaguez Medical Center</name>
      <address>
        <city>Mayaguez</city>
        <zip>00681</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 12, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2013</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

